Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers?

Pardi, D. S.; Sandborn, W. J.
March 2005
Gut;Mar2005, Vol. 54 Issue 3, p321
Academic Journal
The article reports that predicting relapse in patients with inflammatory bowel disease. Various laboratory biomarkers have been studied in inflammatory bowel disease (IBD) as diagnostic aids, indicators of disease activity or severity, and to predict the risk of relapse in those patients in remission. These biomarkers have enormous potential implications for patient management. For example, therapeutic decisions could be directed more appropriately if a marker could reliably distinguish active IBD from other inflammatory or non- inflammatory causes of symptoms, or if one could distinguish Crohn's disease from ulcerative colitis.


Related Articles

  • Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease. Hoekman, Daniël; Diederen, Kay; Koot, Bart; Tabbers, Merit; Kindermann, Angelika; Benninga, Marc; Hoekman, Daniël R; Koot, Bart G P; Tabbers, Merit M; Benninga, Marc A // European Journal of Pediatrics;Oct2016, Vol. 175 Issue 10, p1335 

    Unlabelled: In adult inflammatory bowel disease (IBD) patients, there is a strong discrepancy between symptoms and biomarkers of inflammation. Data on pediatric IBD patients are conflicting. Therefore, we aimed to investigate the relationship between clinical symptoms and biomarkers...

  • Consumption of Dental Treatment in Patients with Inflammatory Bowel Disease, a Register Study. Johannsen, Annsofi; Fored, Michael C.; Håkansson, Jan; Ekbom, Anders; Gustafsson, Anders // PLoS ONE;8/12/2015, Vol. 10 Issue 8, p1 

    Objective: The aim of this study was to compare the consumption of dental treatment among patients with Crohn´s disease (CD) or ulcerative colitis (UC) compared to age and gender matched control groups. Design: The study group comprised 2085 patients with CD and 3161 with UC from the...

  • Racial Differences in Disease Activity and Quality of Life in Patients with Crohn's Disease. Ghazi, Leyla; Lydecker, Alison; Patil, Seema; Rustgi, Ankur; Cross, Raymond; Flasar, Mark // Digestive Diseases & Sciences;Oct2014, Vol. 59 Issue 10, p2508 

    Background: The existing literature on racial differences in Crohn's disease (CD) activity and quality of life (QOL) is limited and extrapolated from surrogate measures. Aim: The aim of our study was to compare objective markers of disease activity and QOL over time by race. Study: A clinical...

  • New serological biomarkers of inflammatory bowel disease. Xuhang Li; Conklin, Laurie; Alex, Philip; Mizoguchi, Emiko // World Journal of Gastroenterology;9/7/2008, Vol. 14 Issue 33, p5115 

    Serological biomarkers in inflammatory bowel disease (IBD) are a rapidly expanding list of non-invasive tests for objective assessments of disease activity, early diagnosis, prognosis evaluation and surveillance. This review summarizes both old and new biomarkers in IBD, but focuses on the...

  • Gut Microbes in Crohn's Disease: Getting to Know You Better? Murphy, Seamus J.; Ullman, Thomas A.; Abreu, Maria T. // American Journal of Gastroenterology;Feb2008, Vol. 103 Issue 2, p397 

    Biomarkers in inflammatory bowel disease (IBD) are needed to help in disease diagnosis, prognosis, and assessment of disease activity. The best serologic markers to date measure antibody responses to normal commensal flora. These antibody responses can provide prognostic information as well as...

  • New data on Cimzia (certolizumab pegol) to be presented at ACG meeting highlights role of inflammatory biomarkers in treatment for moderate to severe Crohn's disease.  // Biomedical Market Newsletter;10/31/2011, Vol. 21, p106 

    The article reports that UCB Inc. in Atlanta, Georgia will present data on Cimzia at the American College of Gastroenterology Annual Scientific Meeting in Washington, D. C. from October 28 to November 2, 2011. According to Doctor William Sandborn, the Cimzia data will highlight the role that...

  • Management of Crohn's disease in poor responders to adalimumab. de Boer, Nanne K. H.; Löwenberg, Mark; Hoentjen, Frank // Clinical & Experimental Gastroenterology;2014, Vol. 7, p83 

    Anti-tumor necrosis factor therapy with adalimumab is an effective therapy for the induction and maintenance of remission in moderate to severe Crohn's disease. Although a large proportion of patients show a favorable clinical response to adalimumab, therapy failure is common. In this review, we...

  • Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls.  // Inflammatory Bowel Disease Monitor;2010, Vol. 10 Issue 4, p137 

    This study compared psychological functioning and health perceptions in a community IBD patient sample with those in a matched community non-IBD sample of individuals. Overall, the IBD sample had lower psychological wellbeing and mastery, as well as higher distress levels than the non-IBD...

  • Crohn's disease: why the disparity in mortality? Loftus Jr., E. V. // Gut;Apr2006, Vol. 55 Issue 4, p447 

    The article comments on a study conducted by F.L. Wolters and colleagues titled "Crohn's Disease: Increased Mortality 10 Years After Diagnosis in a Europe-Wide Population-Based Cohort." The author cites the strengths and weaknesses of the EC-IBD mortality study. He also compares the EC-IBD study...


Read the Article


Sign out of this library

Other Topics